BeStock  
Stocks › Biotechnology › MLYS

Mineralys Therapeutics MLYS

US equityMarket cap rank #3034Biotechnology
$13.66 −$0.50 (-3.53%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $13.70 +0.29%
Open$13.81
Prev close$14.16
Day range$13.57 – $14.79
Volume1.35M
Market cap$1.21B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership115.9%+0.12 pts vs. prior quarter
Institutions holding294+4 vs. prior quarter
Insider trades (recent)7 buys / 43 sellsNet selling
Short interest8.70% of floatDays to cover 5.0 · as of 30 Oct 2026
Short-sale volume share21.4%5-day average of daily volume

Short-sale volume as % of daily volume

2%15%28%41%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$14.14M (3 inflow days, 17 outflow days).

Net flow by order size, last 20 sessions

−$12.0MSuper−$2.1MBig+$3.6MMid+$412.4KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 36.4% of shares outstanding.

Largest holders

  • Catalys Pacific8.81%
  • RA Capital Management, L.P.8.69%
  • BlackRock6.97%
  • Samsara BioCapital LLC6.63%
  • FMR5.32%
  • Deerfield Management Company, L.P.4.47%
  • Vanguard Capital Management, LLC3.36%
  • State Street Global Advisors3.25%

By investor type

  • Mutual Fund49.87%
  • VC/PE Fund31.66%
  • Hedge Fund26.98%
  • Public Company4.38%
  • Private Company1.49%
  • Sovereign Wealth Fund0.93%
  • Individual/Insider0.51%
  • Government Pension Fund0.32%

Reported short interest has fallen from 10.91% to 8.70% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Capital Research Mutual Fund 2026/Q3 +573,525 2.9%
BlackRock Mutual Fund 2026/Q3 +285,115 7.0%
abrdn plc Mutual Fund 2026/Q3 +243,123 1.1%
American Century Investment Management Mutual Fund 2026/Q3 +235,297 1.4%
Deerfield Management Company, L.P. Hedge Fund 2026/Q3 +3,958,000 4.5%
Capital Research Mutual Fund 2026/Q3 +1,599,428 2.3%
BlackRock Mutual Fund 2026/Q3 +1,405,456 6.7%
State Street Global Advisors Mutual Fund 2026/Q3 +1,205,696 4.7%
Ghisallo Capital Management LLC Hedge Fund 2026/Q3 +1,125,000 1.3%
Troluce Capital Advisors, LLC Mutual Fund 2026/Q3 +1,073,753 2.0%
Logos Global Management, L.P. Hedge Fund 2026/Q3 +1,050,000 1.2%
Invesco Ltd. Mutual Fund 2026/Q3 +1,046,753 1.2%
T. Rowe Price Group, Inc. Mutual Fund 2026/Q3 +919,163 2.6%
Millennium Management LLC Hedge Fund 2026/Q3 +696,498 1.4%
abrdn plc Mutual Fund 2026/Q3 +689,235 0.8%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
18 Oct 2026 Kristine Peterson Director Other Acquisition +12,400 – 12,400
18 Oct 2026 Kristine Peterson Director Other Derivative Acquisition +16,600 $20.92 16,600
18 Oct 2026 Lonnel Coats Director Other Acquisition +12,400 – 12,400
18 Oct 2026 Lonnel Coats Director Other Derivative Acquisition +16,600 $20.92 16,600
12 Oct 2026 David Rodman Former Chief Medical Officer Intent to Sell (Form 144) -3,542 $22.04 –
29 Sep 2026 Jon Congleton Chief Executive Officer Automatic Disposition -75,000 $25.46 387,721
21 Sep 2026 Catalys Pacific Open Market Disposition -104,320 $28.81 7,799,518
20 Sep 2026 Eric Warren Chief Commercial Officer Derivative Exercise and Sale -7,438 $28.12 38,400
16 Sep 2026 David Rodman Former Chief Medical Officer Intent to Sell (Form 144) -417 $27.95 –
14 Sep 2026 Daphne Karydas Independent Director Derivative Exercise and Sale -3,000 $28.58 6,200
13 Sep 2026 David Rodman Former Chief Medical Officer Intent to Sell (Form 144) -7,709 $28.14 –
8 Sep 2026 David Rodman Former Chief Medical Officer Intent to Sell (Form 144) -2,171 $30.87 –
20 Aug 2026 Eric Warren Chief Commercial Officer Derivative Exercise and Sale -7,437 $25.98 38,400
16 Aug 2026 David Rodman Former Chief Medical Officer Intent to Sell (Form 144) -417 $25.46 –
12 Aug 2026 David Rodman Former Chief Medical Officer Intent to Sell (Form 144) -14,056 $26.48 –
9 Aug 2026 James Ferguson Chief Medical Officer Other Acquisition +102,400 – 102,400
9 Aug 2026 James Ferguson Chief Medical Officer Other Derivative Acquisition +135,000 $27.38 135,000
9 Aug 2026 David Rodman Former Chief Medical Officer Derivative Exercise and Sale -2,170 $27.09 12,984
20 Jul 2026 Eric Warren Chief Commercial Officer Derivative Exercise and Sale -7,438 $26.87 38,400
16 Jul 2026 David Rodman Former Chief Medical Officer Derivative Exercise and Sale -416 $26.53 12,984

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 7,687,327 8.7% 5.0
15 Oct 2026 7,438,452 8.4% 5.3
30 Sep 2026 7,805,612 8.8% 5.2
15 Sep 2026 9,181,891 10.4% 6.4
31 Aug 2026 9,332,307 10.6% 11.4
14 Aug 2026 9,645,951 10.9% 13.0

Discussion

No comments yet — be the first to weigh in on MLYS.

Sign in to join the discussion.

Scroll to Top